Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients

Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated substitutions (RASs) before and after treatment. Indeed, RASs detected in DAA treatm...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijä: Aldunate Caramori, Fabián (author)
Muut tekijät: Echeverría Chagas, Natalia (author), Chiodi, Daniela (author), López, Pablo (author), Sánchez Cicerón, Adriana (author), Fajardo Rossi, Álvaro (author), Sóñora, Martín (author), Cristina, Juan (author), Hernández, Nelia (author), Moreno Karlen, María del Pilar (author)
Aineistotyyppi: article
Kieli:englanti
Julkaistu: 2018
Aiheet:
Linkit:https://hdl.handle.net/20.500.12008/22071
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
_version_ 1868890138580353024
author Aldunate Caramori, Fabián
author2 Echeverría Chagas, Natalia
Chiodi, Daniela
López, Pablo
Sánchez Cicerón, Adriana
Fajardo Rossi, Álvaro
Sóñora, Martín
Cristina, Juan
Hernández, Nelia
Moreno Karlen, María del Pilar
author2_role author
author
author
author
author
author
author
author
author
author_browse Aldunate Caramori, Fabián
Chiodi, Daniela
Cristina, Juan
Echeverría Chagas, Natalia
Fajardo Rossi, Álvaro
Hernández, Nelia
López, Pablo
Moreno Karlen, María del Pilar
Sánchez Cicerón, Adriana
Sóñora, Martín
author_facet Aldunate Caramori, Fabián
Echeverría Chagas, Natalia
Chiodi, Daniela
López, Pablo
Sánchez Cicerón, Adriana
Fajardo Rossi, Álvaro
Sóñora, Martín
Cristina, Juan
Hernández, Nelia
Moreno Karlen, María del Pilar
author_role author
collection COLIBRI
dc.contributor.none.fl_str_mv Aldunate Caramori, Fabián. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
Echeverría Chagas, Natalia. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
Chiodi, D.
López, P.
Sánchez-Cicerón, A.
Fajardo Rossi, Álvaro. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
Soñora, Martín. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
Cristina, Juan. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
Hernández, Nelia
Moreno Karlen, María del Pilar. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares
dc.creator.none.fl_str_mv Aldunate Caramori, Fabián
Echeverría Chagas, Natalia
Chiodi, Daniela
López, Pablo
Sánchez Cicerón, Adriana
Fajardo Rossi, Álvaro
Sóñora, Martín
Cristina, Juan
Hernández, Nelia
Moreno Karlen, María del Pilar
dc.date.none.fl_str_mv 2018
2019-10-02T22:14:42Z
2019-10-02T22:14:42Z
20191001
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv Aldunate Caramori, F. y otros. "Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients". Disease Markers, 2018, art. no. 2514901. doi: 10.1155/2018/2514901
0278-0240
https://hdl.handle.net/20.500.12008/22071
10.1155/2018/2514901
dc.language.none.fl_str_mv en
eng
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.relation.none.fl_str_mv Disease Markers, 2018, art. no. 2514901
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
Licencia Creative Commons Atribución (CC –BY 4.0)
dc.source.none.fl_str_mv reponame:COLIBRI
instname:Universidad de la República
instacron:Universidad de la República
dc.subject.none.fl_str_mv Hepacivirus
Hepatitis C
Antivirals DAAs
dc.title.none.fl_str_mv Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
dc.type.none.fl_str_mv Artículo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
description Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated substitutions (RASs) before and after treatment. Indeed, RASs detected in DAA treatment-naïve HCV-infected patients could be useful for clinical management and outcome prediction. Although the frequency of naturally occurring HCV NS5A and NS5B RASs has been addressed in many countries, there are only a few reports on their prevalence in the South American region. The aim of this study was to investigate the presence of RASs to NS5A and NS5B inhibitors in a DAA treatment naïve cohort of Uruguayan patients infected with chronic hepatitis C and compare them with reports from other South American countries. Here, we found that naturally occurring substitutions conferring resistance to NS5A and NS5B inhibitors were present in 8% and 19.2,% respectively, of treatment-naïve HCV genotype 1 infected patients. Importantly, the baseline substitutions in NS5A and NS5B herein identified differ from the studies previously reported in Brazil. Furthermore, Uruguayan strains subtype 1a clustered within all major world clades, showing that HCV variants currently circulating in this country are characterized by a remarkable genetic diversity.
eu_rights_str_mv openAccess
format article
id anni_94a2c98c05cdc4a6a91f20dde76a8f13
identifier_str_mv Aldunate Caramori, F. y otros. "Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients". Disease Markers, 2018, art. no. 2514901. doi: 10.1155/2018/2514901
0278-0240
10.1155/2018/2514901
instacron_str Universidad de la República
institution Universidad de la República
instname_str Universidad de la República
language eng
language_invalid_str_mv en
network_acronym_str anni
network_name_str oai-lr-anni
oai_identifier_str oai:colibri.udelar.edu.uy:20.500.12008/22071
publishDate 2018
publishDateSort 2018
publisher.none.fl_str_mv Hindawi Publishing Corporation
reponame_str COLIBRI
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv Licencia Creative Commons Atribución (CC –BY 4.0)
spelling Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patientsAldunate Caramori, FabiánEcheverría Chagas, NataliaChiodi, DanielaLópez, PabloSánchez Cicerón, AdrianaFajardo Rossi, ÁlvaroSóñora, MartínCristina, JuanHernández, NeliaMoreno Karlen, María del PilarHepacivirusHepatitis CAntivirals DAAsHepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated substitutions (RASs) before and after treatment. Indeed, RASs detected in DAA treatment-naïve HCV-infected patients could be useful for clinical management and outcome prediction. Although the frequency of naturally occurring HCV NS5A and NS5B RASs has been addressed in many countries, there are only a few reports on their prevalence in the South American region. The aim of this study was to investigate the presence of RASs to NS5A and NS5B inhibitors in a DAA treatment naïve cohort of Uruguayan patients infected with chronic hepatitis C and compare them with reports from other South American countries. Here, we found that naturally occurring substitutions conferring resistance to NS5A and NS5B inhibitors were present in 8% and 19.2,% respectively, of treatment-naïve HCV genotype 1 infected patients. Importantly, the baseline substitutions in NS5A and NS5B herein identified differ from the studies previously reported in Brazil. Furthermore, Uruguayan strains subtype 1a clustered within all major world clades, showing that HCV variants currently circulating in this country are characterized by a remarkable genetic diversity.Hindawi Publishing CorporationAldunate Caramori, Fabián. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones NuclearesEcheverría Chagas, Natalia. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones NuclearesChiodi, D.López, P.Sánchez-Cicerón, A.Fajardo Rossi, Álvaro. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones NuclearesSoñora, Martín. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones NuclearesCristina, Juan. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones NuclearesHernández, NeliaMoreno Karlen, María del Pilar. Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares2019-10-02T22:14:42Z2019-10-02T22:14:42Z201820191001Artículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfAldunate Caramori, F. y otros. "Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients". Disease Markers, 2018, art. no. 2514901. doi: 10.1155/2018/25149010278-0240https://hdl.handle.net/20.500.12008/2207110.1155/2018/2514901reponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaenengDisease Markers, 2018, art. no. 2514901Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad De La República. (Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC –BY 4.0)oai:colibri.udelar.edu.uy:20.500.12008/220712026-04-14T10:09:19Z
spellingShingle Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
Aldunate Caramori, Fabián
Hepacivirus
Hepatitis C
Antivirals DAAs
status_str publishedVersion
title Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
title_full Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
title_fullStr Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
title_full_unstemmed Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
title_short Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
title_sort Pretreatment Hepatitis C Virus NS5A/NS5B resistance-associated substitutions in genotype 1 uruguayan infected patients
topic Hepacivirus
Hepatitis C
Antivirals DAAs
url https://hdl.handle.net/20.500.12008/22071